ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1578

Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis

Francis Lao1, Cal Robinson2, Megan Schlorff1, Joycelynn Ewusie3, KAREN BEATTIE1 and Michelle Batthish1, 1McMaster University, Hamilton, ON, Canada, 2The Hospital for Sick Children, Hamilton, ON, Canada, 3St Joseph's Healthcare Hamilton, Hamilton, ON, Canada

Meeting: ACR Convergence 2022

Keywords: Cardiovascular, meta-analysis, Pediatric rheumatology, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Kawasaki Disease (KD) is a common childhood vasculitis. Coronary artery aneurysms (CAAs) develop in approximately 25% of untreated KD patients. However, there is limited data on the long-term rate cardiovascular events following childhood KD diagnosis, especially in the post-IVIG era. We aimed to determine the prevalence of myocardial infarction (MI), heart failure (HF), and cardiac arrest, referred to as composite cardiovascular events (CV) and mortality following KD diagnosis.

Methods: We performed a literature search using 5 databases until 2019. We retrieved English articles for review including randomized-controlled trials, cross-sectional studies, case-control studies, cohort studies, and abstracts. Inclusion criteria included patients 0-18 years at KD diagnosis with a minimum follow-up >1 year. The search produced 170 full-text articles for data extraction (Figure 1) of the incidence of CV events (MI, HF and cardiac arrest) and mortality. The Newcastle-Ottawa Scale assessed study quality focusing on participant selection, comparability, and measurement of outcome or ascertainment of exposure. The study was submitted to PROSPERO on 23 November 2019 and registered on 28 April 2020. Subgroup analysis for CAA presence and IVIG use was performed.

Results: Among 113,903 KD patients across 170 studies, there were 1521 and 1140 cases of CV events (MI, heart failure, or cardiac arrest) and death, respectively. Eighty-four studies followed patients for ³ 5 years. Meta-analyses generated a prevalence of CV events of 1.05% and death of 0.30%. Among studies where all participants had CAAs, the prevalence was 3794 and 1133 per 100,000 for CV events and death, respectively. For studies where none or few of the participants had CAAs (< 10% of participants), the prevalence was 33 and 134 per 100,000 for CV events and death, respectively (Table 1). Among studies where all participants received IVIG, the prevalence was 57 and 166 per 100,000 for CV events and death, respectively. For studies where none or few of the participants received IVIG, the prevalence was 2310 and 628 per 100,000 for cardiovascular events and death, respectively (Table 2).

Conclusion: This study comprises the largest systematic review and meta-analysis of long-term cardiovascular outcomes and mortality following KD diagnosis. The low prevalence of mortality (< 1%) and lower prevalence of CV events for patients without CAAs can provide reassurance to families over the long-term. Those with CAAs, however, have higher prevalence of cardiovascular events which highlights the need for CAA surveillance, monitoring, and potential intervention to prevent development of these events.

Supporting image 1

Figure 1: PRISMA flow diagram of study selection

Supporting image 2

Table 1: Summary of primary and secondary outcomes, among all studies, and by coronary artery aneurysm status

Supporting image 3

Table 2: Summary of primary outcomes and subgroup analysis by IVIG treatment.


Disclosures: F. Lao, None; C. Robinson, None; M. Schlorff, None; J. Ewusie, None; K. BEATTIE, None; M. Batthish, None.

To cite this abstract in AMA style:

Lao F, Robinson C, Schlorff M, Ewusie J, BEATTIE K, Batthish M. Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/long-term-cardiovascular-disease-and-mortality-following-kawasaki-disease-in-childhood-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-cardiovascular-disease-and-mortality-following-kawasaki-disease-in-childhood-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology